Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

1(25.0%)

Phase 1

1(25.0%)

Phase 4

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(1)

Phase 1(1)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03836144Completed

Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria

Role: collaborator

NCT02227316Phase 4Completed

Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure

Role: collaborator

NCT00670150Phase 2Withdrawn

New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia

Role: collaborator

NCT00668902Not ApplicableCompleted

Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole

Role: collaborator

NCT00668499Phase 1Withdrawn

A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma

Role: collaborator

All 5 trials loaded